Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Zealand Pharma - Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
GlobeNewswire

Company announcement – No. 22 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL)…

globenewswire.com - Zealand Pharma - Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
GlobeNewswire

Company announcement No. 23 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 23, 2026) Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL)…

cnbc.com - Elsa Ohlen - The space race is coming for pharma: Why drug development is heading to lower Earth orbit
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
CNBC

Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of companies is capitalizing on space, which allows…

cnbc.com - Katie Stockton - Pharma stocks are showing strength. Charts predict this name could break out next
Pharma stocks are showing strength. Charts predict this name could break out next
CNBC

Pharmaceutical stocks have recently separated themselves from the broader market, and the group has become an increasingly important source of leadership within healthcare. Eli Lilly is the bellwether in the space and has already broken out to…

yahoo.com - Fahad Saleem - Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026
Yahoo!

10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Druckenmiller's Stake:…

bloomberg.com - Stock Movers: Monte Dei Paschi, Tate & Lyle, Zealand Pharma
Stock Movers: Monte Dei Paschi, Tate & Lyle, Zealand Pharma
Bloomberg

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street. Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for…

thehindubusinessline.com - India ready to open pharma market to innovative global products: Goyal
India ready to open pharma market to innovative global products: Goyal
BusinessLine

India is willing to open its market to high-quality and innovative products from the global pharma sector in return for preferential access for the domestic drug exports, Commerce and Industry Minister Piyush Goyal said on Monday. He said that the…

marketbeat.com - Capital World Investors Raises Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS
Capital World Investors Raises Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS
MarketBeat

Capital World Investors raised its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The…

thehindubusinessline.com - Lupin partners with Spanish pharma company Laboratorios ERN on respiratory drug, for Spain
Lupin partners with Spanish pharma company Laboratorios ERN on respiratory drug, for Spain
BusinessLine

Lupin Limited is partnering with Spanish pharma company Laboratorios ERN SA to launch its fixed dose combination Luforbec (beclometasone/formoterol), in Spain. The drug, administered through a pressurized metered dose inhaler (pMDI), is used to…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Time to Buy?
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Time to Buy?
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) reached a new 52-week high during trading on Monday. The company traded as high as $56.29 and last traded at $56.3110, with a volume of 2862 shares traded. The stock had previously closed at…

rediff.com - Sohini Das, Prachi Pisal, Gulveen Aulakh, Auhona Mukherjee, Shine Jacob, Ishita Ayan Dutt - India Inc Battles Rising Gulf War Costs
India Inc Battles Rising Gulf War Costs
Rediff.com

Companies are already diversifying sourcing, raising prices, and reworking operating models as the disruption drags on. Prolonged West Asia conflict is raising freight, insurance and input costs across multiple sectors of India Inc. Automobile and…

forbes.com - Adam Wolfberg - The 'New' New Way To Sell Prescription Medications
The 'New' New Way To Sell Prescription Medications
Forbes

Adam Wolfberg, MD, is chief medical officer at Virta Health, where he leads a clinical team focused on treatment of diabetes and obesity. ​The fastest, least-expensive way to find a doctor who will prescribe Zepbound for weight loss may be…

fool.com - Adria Cimino - Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway
Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway
The Motley Fool

The S&P 500 has roared higher over the past three years -- and since President Donald Trump's inauguration in January of last year, the famous benchmark has advanced more than 23%. Investors have rushed to buy high-growth players, particularly in…

statnews.com - Andrew Joseph - GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
STAT

LONDON — GSK said Tuesday it would buy the cancer-focused biotech Nuvalent in a deal worth $10.6 billion, as the British firm continues its expansion in oncology. The deal is the latest in a run of biopharma acquisitions in recent months, as…

seekingalpha.com - Fidelity Investments - Fidelity Select Health Care Portfolio Q1 2026 Commentary (FSPHX)
Fidelity Select Health Care Portfolio Q1 2026 Commentary (FSPHX)
Seeking Alpha

Stock picking is the core of our investment process and relies on fundamental, bottom-up research. For the quarter, the Fidelity Select Health Care Portfolio returned -6.16%, lagging the MSCI health care index. The Fidelity Select Health Care…

Receive a Daily briefing on Pharma Industry News

Get Started